Compare Adaptive Biotechnologies Corp (ADPT) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M). The key difference: Adaptive Biotechnologies Corp is far larger — about 263.5× Avalanche Treasury Corporation Class A Common Stock's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ADPT | AVAT | |
|---|---|---|
Market Cap | $4.04B | $15.33M |
Sector | Health | Financials |
52-Week High | $25.45 | $10.75 |
52-Week Low | $12.30 | $0.30 |
Enterprise Value | $4.10B | $15.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
AVAT trades at $0.3426, up 1.75% today, with a bearish technical signal from moving averages and a P/E of 12. The company reported net income of $8.28 million for 2025, but negative operating cash flow of $930,710 raises concerns about liquidity. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed: profitability and low valuation offer potential upside, but cash flow challenges and bearish technicals present risks. Investor sentiment is cautious due to operational losses, though the public listing may attract institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
